Gene Therapy Trial at the Retina Foundation of the Southwest featured in The Dallas Morning News
Mason Two Crow, 22, first came to the Retina Foundation in 2003 with a diagnosis of X-linked retinoschisis, a rare genetic condition affecting the retina. Two years ago he came in for a follow-up appointment where he learned that he had the opportunity to be one of the very first to ever be enrolled in a gene therapy trial for his rare eye disease. Mason gives credit to the research scientists at the Retina Foundation for gifting him with the hope that a cure for X-linked retinoschisis may be on the horizon. Click here to read more of Mason’s incredible story on www.dallasnews.com.

Related Articles
Two New Postdoctoral Fellowships Begin in the Molecular Ophthalmology Laboratory Three Patents Awarded for Retina Foundation’s Two-Layer Ocular Implant in Japan, Europe and the United States Choroideremia Research Is Necessary to Help Prevent Blindness at an Early Age Discovering New Therapies for AMD Investigating Reading Readiness in Preschool Children with Amblyopia (Lazy Eye)